NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Stock Forecast, Price & News

$23.98

-0.07 (-0.29%)

(As of 05/31/2023 ET)

Compare

Today's Range: $23.30
▼
$24.75
50-Day Range: $18.95
▼
$25.32
52-Week Range: $12.08
▼
$33.49

Volume: 154,265 shs
Average Volume: 289,920 shs
Market Capitalization: $511.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $53.20

Bicycle Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.91 Rating Score
Upside/Downside: 122.2% Upside
$53.20 Price Target
Short Interest: Bearish
19.90% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.37
Based on 5 Articles This Week
Insider Trading: Selling Shares
$55,477 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($4.91) to ($5.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

908th out of 1,006 stocks

Pharmaceutical Preparations Industry

451st out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Bicycle Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $53.20, Bicycle Therapeutics has a forecasted upside of 122.2% from its current price of $23.94.
Amount of Analyst Coverage
Bicycle Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
19.90% of the outstanding shares of Bicycle Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Bicycle Therapeutics has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Bicycle Therapeutics has recently increased by 15.22%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Bicycle Therapeutics does not currently pay a dividend.
Dividend Growth
Bicycle Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCYC.

1.3

News and Social Media Coverage

News Sentiment
Bicycle Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Bicycle Therapeutics this week, compared to 7 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,477.00 in company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Bicycle Therapeutics is held by insiders.
Percentage Held by Institutions
77.88% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($4.91) to ($5.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bicycle Therapeutics is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bicycle Therapeutics is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bicycle Therapeutics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

May 31, 2023 | msn.com

Brownsville’s Bicycle, Pedestrian and Child Safety Campaign

May 28, 2023 | es-us.finanzas.yahoo.com

NYC Bicycle Accident Lawyer Glenn A. Herman Advocacy on Bicycle Accident Statistics in NYC in 2023

May 31, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 27, 2023 | es-us.finanzas.yahoo.com

Bicycle Market Trends and ForecastThe global bicycle market is expected to reach an estimated $99.5 billion by 2028 with a CAGR of 5.9% 2022 to 2028

May 25, 2023 | msn.com

New Bicycle Helmets Being Collected For Red Bank Giveaway

May 18, 2023 | seekingalpha.com

Bicycle Therapeutics (BCYC) Investor Presentation - Slideshow

May 17, 2023 | msn.com

Bicycle Therapeutics's Return On Capital Employed Insights

May 14, 2023 | finance.yahoo.com

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

May 31, 2023 | Legacy Research (Affiliate) (Ad)

Sell every Stock except ONE

Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...

May 14, 2023 | seekingalpha.com

Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet

May 13, 2023 | americanbankingnews.com

Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $53.20 Average Price Target from Brokerages

May 12, 2023 | barrons.com

Bicycle Therapeutics and Orano Med Present Preclinical Bicycle(R) Radio-Conjugate Data at TIDES 2023

May 11, 2023 | marketwatch.com

8-K: BICYCLE THERAPEUTICS plc

May 11, 2023 | markets.businessinsider.com

14 Analysts Have This to Say About Bicycle Therapeutics

May 11, 2023 | finance.yahoo.com

Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023

May 10, 2023 | bizjournals.com

Bayer inks $1.7B deal with Bicycle Therapeutics

May 10, 2023 | markets.businessinsider.com

Bayer In Deal With Bicycle Therapeutics To Develop Radionuclide Therapies

May 10, 2023 | reuters.com

Bayer, Bicycle Therapeutics in cancer radiotherapy drug alliance

May 10, 2023 | finance.yahoo.com

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

May 9, 2023 | msn.com

Oppenheimer Reiterates Bicycle Therapeutics Plc - ADR (BCYC) Outperform Recommendation

May 9, 2023 | americanbankingnews.com

Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasted to Post FY2027 Earnings of $9.24 Per Share

May 6, 2023 | msn.com

HC Wainwright & Co. Reiterates Bicycle Therapeutics Plc - ADR (BCYC) Buy Recommendation

May 6, 2023 | nasdaq.com

Needham Maintains Bicycle Therapeutics Plc - ADR (BCYC) Buy Recommendation

May 5, 2023 | usnews.com

France to Spend 2 Billion Euros to Boost Bicycle Usage

May 5, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)

May 5, 2023 | msn.com

PennDOT provides reminders for National Bicycle Safety Month

May 4, 2023 | finance.yahoo.com

Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Company Calendar

Last Earnings: 11/03/2021
Today: 5/31/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCYC
CUSIP: N/A
CIK: 1761612
Web: www.bicycletherapeutics.com
Phone: 441223261503
Fax: N/A
Employees: 119
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $53.20
High Stock Price Forecast: $74.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +121.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.91
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,720,000.00
Net Margins: -801.45%
Pretax Margin: -812.57%
Return on Equity: -44.57%
Return on Assets: -29.19%

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 7.19
Quick Ratio: 7.19

Sales & Book Value

Annual Sales: $14.46 million
Price / Sales: 35.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.41 per share
Price / Book: 2.10

Miscellaneous

Outstanding Shares: 21,310,000
Free Float: 19,388,000
Market Cap: $511.44 million
Optionable: Not Optionable
Beta: 0.75

Key Executives

Kevin Lee
Chief Executive Officer & Executive Director

Lee H. Kalowski
President & Chief Financial Officer

Alistair Milnes
Chief Operating Officer

Michael Skynner
Chief Technology Officer

Nicholas Keen
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCYC Stock - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings or view top-rated stocks.
What is Bicycle Therapeutics' stock price forecast for 2023?: 11 Wall Street research analysts have issued 12-month price targets for Bicycle Therapeutics' shares. Their BCYC share price forecasts range from $30.00 to $74.00. On average, they anticipate the company's stock price to reach $53.20 in the next year. This suggests a possible upside of 121.7% from the stock's current price.
View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts.
How have BCYC shares performed in 2023?: Bicycle Therapeutics' stock was trading at $29.60 at the start of the year. Since then, BCYC stock has decreased by 18.9% and is now trading at $24.00.
View the best growth stocks for 2023 here.
When is Bicycle Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BCYC earnings forecast.
How were Bicycle Therapeutics' earnings last quarter?: Bicycle Therapeutics plc (NASDAQ:BCYC) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.02. The business earned $4.33 million during the quarter, compared to the consensus estimate of $5.29 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 44.57% and a negative net margin of 801.45%.
What ETFs hold Bicycle Therapeutics' stock?: ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Horizon Kinetics Medical ETF (MEDX), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Harbor Disruptive Innovation ETF (INNO), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and
What other stocks do shareholders of Bicycle Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

When did Bicycle Therapeutics IPO?: (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is Bicycle Therapeutics' stock symbol?: Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."
Who are Bicycle Therapeutics' major shareholders?: Bicycle Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Candriam S.C.A. (6.12%), Sio Capital Management LLC (4.54%), Logos Global Management LP (3.52%), Armistice Capital LLC (3.45%), First Light Asset Management LLC (3.28%) and AXA S.A. (2.16%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends.
How do I buy shares of Bicycle Therapeutics?: Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bicycle Therapeutics' stock price today?: One share of BCYC stock can currently be purchased for approximately $24.00.
How much money does Bicycle Therapeutics make?: Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $511.44 million and generates $14.46 million in revenue each year. The company earns $-112,720,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis.
How many employees does Bicycle Therapeutics have?: The company employs 119 workers across the globe.
How can I contact Bicycle Therapeutics?: Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503 or via email at david.borah@bicycletx.com.

This page (NASDAQ:BCYC) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial